comparemela.com

Latest Breaking News On - Icon public - Page 5 : comparemela.com

ICON Public Limited (NASDAQ:ICLR) Sees Large Decline in Short Interest

ICON Public Limited (NASDAQ:ICLR – Get Free Report) was the recipient of a significant drop in short interest during the month of December. As of December 15th, there was short interest totalling 1,550,000 shares, a drop of 7.7% from the November 30th total of 1,680,000 shares. Based on an average trading volume of 522,000 shares, […]

Motco Purchases 138 Shares of ICON Public Limited (NASDAQ:ICLR)

Motco increased its holdings in shares of ICON Public Limited (NASDAQ:ICLR – Free Report) by 1,254.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 149 shares of the medical research company’s stock after purchasing an additional 138 shares during the quarter. […]

ICON Public (NASDAQ:ICLR) Issues FY 2023 Earnings Guidance

ICON Public (NASDAQ:ICLR – Get Free Report) issued an update on its FY 2023 earnings guidance on Wednesday morning. The company provided EPS guidance of $12.63-$12.91 for the period, compared to the consensus EPS estimate of $12.74. The company issued revenue guidance of $8.07 billion-$8.21 billion, compared to the consensus revenue estimate of $8.15 billion. […]

ICON Public (NASDAQ:ICLR) Releases FY23 Earnings Guidance

ICON Public (NASDAQ:ICLR – Get Free Report) issued an update on its FY23 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $12.63-12.91 for the period, compared to the consensus earnings per share estimate of $12.72. The company issued revenue guidance of $8.07-8.21 billion, compared to the consensus revenue estimate of […]

ICON Public (NASDAQ:ICLR) Price Target Increased to $287 00 by Analysts at Robert W Baird

ICON Public (NASDAQ:ICLR – Get Free Report) had its target price hoisted by Robert W. Baird from $278.00 to $287.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Robert W. Baird’s target price would suggest a potential […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.